ReviewJournal of hematology & oncology2012
Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.
Review in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.BMC medicine · 2024Trial
- Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD.International journal of hematology · 2019Trial
- Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.Journal of hematology & oncology · 2012Trial
- Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.Annals of hematology · 2026Article
- Nonthermal radiofrequency radiation promotes hematopoietic stem and progenitor cells function by regulating CaStem cell research & therapy · 2026Article
- Plasma exchange combined with anti-B-cell therapy enables comparable outcomes between DSA-positive and DSA-negative aplastic anemia after haplo-HSCT: a propensity-score-matched cohort study.Annals of hematology · 2026Article
- Hidden Toll of CRE Colonization: Tripled Three-Year Mortality Risk and Increased Bloodstream Infection Burden After Allo-HSCT-A Propensity-Adjusted Study.Infection and drug resistance · 2026Article
- Allogeneic Hematopoietic Stem Cell Transplantation as a Therapeutic Approach for Hereditary Diseases.Biomedicines · 2025Review
- A cohort of allogeneic hematopoietic stem cell transplantation for pediatric rare diseases (allo-HSCT-PRD): design and preliminary results.Annals of hematology · 2025Article
- [Effectiveness and safety of belumosudil in 20 patients with chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Immunoglobulin levels of children with bronchiolitis obliterans syndrome after hematopoietic cell transplantation.Frontiers in medicine · 2025Article
- [The prognostic value of colonoscopy grading for acute graft-versus-host disease in patients with malignant hematological disorders after unrelated cord blood transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges.Cell regeneration (London, England) · 2023Review
- Alteration of Meibum Lipidomics Profiling in Patients With Chronic Ocular Graft-Versus-Host Disease.Investigative ophthalmology & visual science · 2023Article
- Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis.Journal of translational medicine · 2023Article
- hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.Journal of hematology & oncology · 2022Article
- Umbilical cord blood transplantation: Still growing and improving.Stem cells translational medicine · 2021Review
- Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models.Bone marrow transplantation · 2021Article
- Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation.Frontiers of medicine · 2019Article
- Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion.Bone marrow transplantation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.